| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Pieris Pharmaceuticals Inc (NASDAQ: PIRS)
PIRS Technical Analysis
5
| As on 13th Dec 2024 PIRS STOCK Price closed @ 13.60 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 1.36 & Strong Buy for SHORT-TERM with Stoploss of 0.25 we also expect STOCK to react on Following IMPORTANT LEVELS. |
PIRSSTOCK Price
| Open | 15.01 | Change | Price | % |
| High | 15.35 | 1 Day | -2.53 | -15.69 |
| Low | 13.26 | 1 Week | -3.10 | -18.56 |
| Close | 13.60 | 1 Month | -3.40 | -20.00 |
| Volume | 51727 | 1 Year | 13.41 | 7057.89 |
| 52 Week High 18.47 | 52 Week Low 0.14 | ||||
NASDAQ USA Most Active Stocks
| HCTI | 0.02 | -33.33% |
| GNLN | 0.01 | -50.00% |
| AMRS | 0.14 | 100.00% |
| NVDA | 141.97 | -2.09% |
| TSLA | 325.31 | 1.94% |
| LMDX | 0.02 | 0.00% |
| NCNA | 0.11 | -26.67% |
| USEG | 2.21 | 55.63% |
| AKTS | 0.04 | 0.00% |
| LCID | 2.10 | -2.78% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| PIRS Daily Charts |
PIRS Intraday Charts |
Whats New @ Bazaartrend |
PIRS Free Analysis |
|
|
PIRS Important Levels Intraday
| RESISTANCE | 17.63 |
| RESISTANCE | 16.34 |
| RESISTANCE | 15.54 |
| RESISTANCE | 14.74 |
| SUPPORT | 12.46 |
| SUPPORT | 11.66 |
| SUPPORT | 10.86 |
| SUPPORT | 9.57 |
PIRS Forecast June 2025
| 4th UP Forecast | 14.26 |
| 3rd UP Forecast | 14.05 |
| 2nd UP Forecast | 13.92 |
| 1st UP Forecast | 13.79 |
| 1st DOWN Forecast | 13.41 |
| 2nd DOWN Forecast | 13.28 |
| 3rd DOWN Forecast | 13.15 |
| 4th DOWN Forecast | 12.94 |
PIRS Weekly Forecast
| 4th UP Forecast | 13.68 |
| 3rd UP Forecast | 13.65 |
| 2nd UP Forecast | 13.64 |
| 1st UP Forecast | 13.62 |
| 1st DOWN Forecast | 13.58 |
| 2nd DOWN Forecast | 13.56 |
| 3rd DOWN Forecast | 13.55 |
| 4th DOWN Forecast | 13.52 |
PIRS Forecast2025
| 4th UP Forecast | 49.33 |
| 3rd UP Forecast | 37.87 |
| 2nd UP Forecast | 30.79 |
| 1st UP Forecast | 23.7 |
| 1st DOWN Forecast | 3.5 |
| 2nd DOWN Forecast | -3.59 |
| 3rd DOWN Forecast | -10.67 |
| 4th DOWN Forecast | -22.13 |
Pieris Pharmaceuticals Inc ( NASDAQ USA Symbol : PIRS )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
PIRS Business Profile
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin protein-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other inflammatory diseases; and lead immune-oncology program comprises Cinrebafusp alfa, a 4-1BB/ HER2 bispecific for the treatment of HER2-expressing solid tumors. The company also develops PRS-344, a bispecific anticalin-antibody fusion protein targeting 4-1BB and PD-L1 for immuno-oncology diseases; and PRS-352, a preclinical-stage program addressing undisclosed targets for immuno-oncology diseases. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. The company also has a clinical trial collaboration and supply agreement with Eli Lilly and Company. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts. Address: 255 State Street, Boston, MA, United States, 02109
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service